There is a continuous relationship between glycaemia and adverse pregnancy outcomes
Gestational diabetes mellitus (GDM) is generally asymptomatic. It is diagnosed by detection of hyperglycaemia resulting from inadequate insulin secretion in response to the increased insulin resistance that occurs during pregnancy. A GDM diagnosis identifies women at risk of pregnancy complications and later progression to type 2 diabetes.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Moynihan RN. Controversy grows over redefinition of gestational diabetes. Med J Aust 2012; 197: 203. <MJA full text>
- 2. Hoffman L, Nolan C, Wilson JD, et al. Gestational diabetes mellitus — management guidelines. The Australasian Diabetes in Pregnancy Society. Med J Aust 1998; 169: 93-97. <MJA full text>
- 3. Landon MB, Spong CY, Thom E, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361: 1339-1348.
- 4. Crowther CA, Hiller JE, Moss JR, et al; Australian Carbohydrate Intolerance Study in Pregnant Women Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352: 2477-2486.
- 5. International Association of Diabetes and Pregnancy Study Groups Consensus Panel Writing Group; Hyperglycemia and Adverse Pregnancy Outcome Study Steering Committee. The diagnosis of gestational diabetes mellitus: new paradigms or status quo? J Matern Fetal Neonatal Med 2012; 25: 2564-2569.
- 6. Landon MB, Mele L, Spong CY, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. The relationship between maternal glycemia and perinatal outcome. Obstet Gynecol 2011; 117: 218-224.
- 7. Mission JF, Ohno MS, Cheng YW, Caughey AB. Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis. Am J Obstet Gynecol 2012; 207: 326.e1-9.
- 8. Werner EF, Pettker CM, Zuckerwise L, et al. Screening for gestational diabetes mellitus: are the criteria proposed by the International Association of the Diabetes and Pregnancy Study Groups cost-effective? Diabetes Care 2012; 35: 529-535.
- 9. Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. Int J Gynaecol Obstet 2011; 115 Suppl 1: S20-S25.
- 10. Moses RG, Morris GJ, Petocz P, et al. The impact of potential new diagnostic criteria on the prevalence of gestational diabetes mellitus in Australia. Med J Aust 2011; 194: 338-340. <MJA full text>
- 11. Dunstan D, Zimmet P, Welborn T, et al; AusDiab Steering Committee. Diabesity and associated disorders in Australia — 2000. The accelerating epidemic. Melbourne: International Diabetes Institute, 2001.
David McIntyre has received research funding from Novo Nordisk, the National Health and Medical Research Council and the Canadian Institutes of Health Research, and travel assistance and payment for presentations from Novo Nordisk, Sanofi-Aventis, Servier, Sonic Healthcare, AstraZeneca and the Australian Diabetes Educators Association.